Royalty Pharma’s $2 billion IPO target shows importance of patent monetisation in life sciences
The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10